FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Masaki Mogi

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Co-author Network

Publications

TOP 3
Fei Jing; Li-Juan Min; Masaki Mogi; Hirotomo Nakaoka; Kousei Ohshima; Kana Tsukuda; Xiaoli Wang; Jun Iwanami; Masatsugu Horiuchi
Effect of Angiotensin II Type 2 Receptor-Interacting Protein on Adipose Tissue Function via Modulation of Macrophage Polarization.
Masaki Mogi; Masatsugu Horiuchi
Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
Kousei Ohshima; Kana Tsukuda; Jitsuo Higaki; Jun Iwanami; Fei Jing; Harumi Kanno; Li-Juan Min; Masaki Mogi; Hirotomo Nakaoka; Akiyoshi Ogimoto; Masatsugu Horiuchi
Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Masaki Mogi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Fei Jing; Li-Juan Min; Masaki Mogi; Hirotomo Nakaoka; Kousei Ohshima; Kana Tsukuda; Xiaoli Wang; Jun Iwanami; Masatsugu Horiuchi
Effect of Angiotensin II Type 2 Receptor-Interacting Protein on Adipose Tissue Function via Modulation of Macrophage Polarization.
PloS one 2013;8(4):e60067.
2013: Masaki Mogi; Masatsugu Horiuchi
Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
Geriatrics & gerontology international 2013;13(1):13-8.
2012: Kousei Ohshima; Kana Tsukuda; Jitsuo Higaki; Jun Iwanami; Fei Jing; Harumi Kanno; Li-Juan Min; Masaki Mogi; Hirotomo Nakaoka; Akiyoshi Ogimoto; Masatsugu Horiuchi
Inhibition of MCP-1/CCR2 signaling pathway is involved in synergistic inhibitory effects of irbesartan with rosuvastatin on vascular remodeling.
Journal of the American Society of Hypertension : JASH 2012;6(6):375-84.
2012: Masaki Mogi; Masatsugu Horiuchi
[Current topic of next generation of angiotensin II type 1 receptor blockers].
Nihon rinsho. Japanese journal of clinical medicine 2012;70(9):1621-6.
2012: Kana Tsukuda; Jun Iwanami; Fei Jing; Li-Juan Min; Masaki Mogi; Kousei Ohshima; Masatsugu Horiuchi
Influence of angiotensin II type 1 receptor-associated protein on prenatal development and adult hypertension after maternal dietary protein restriction during pregnancy.
Journal of the American Society of Hypertension : JASH 2012;6(5):324-30.
2012: Masatsugu Horiuchi; Jun Iwanami; Masaki Mogi
Regulation of angiotensin II receptors beyond the classical pathway.
Clinical science (London, England : 1979) 2012;123(4):193-203.
2012: Li-Juan Min; Masaki Mogi; Kousei Ohshima; Masachika Shudou; Kana Tsukuda; Jun Iwanami; Fei Jing; Masatsugu Horiuchi
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Hypertension 2012;59(5):1079-88.
2012: Li-Juan Min; Masaki Mogi; Kousei Ohshima; Kana Tsukuda; Jun Iwanami; Fei Jing; Masatsugu Horiuchi
Angiotensin II type 2 receptor-interacting protein prevents vascular senescence.
Journal of the American Society of Hypertension : JASH 2012;6(3):179-84.
2012: Akiko Sakata; Kana Tsukuda; Masaharu Ito; Jun Iwanami; Fei Jing; Li-Juan Min; Masaki Mogi; Kousei Ohshima; Masatsugu Horiuchi
Improvement of cognitive impairment in female type 2 diabetes mellitus mice by spironolactone.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2012;13(1):84-90.
2012: Kousei Ohshima; Kana Tsukuda; Jitsuo Higaki; Jun Iwanami; Fei Jing; Li-Juan Min; Masaki Mogi; Masatsugu Horiuchi
Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance.
Hypertension 2012;59(2):493-9.
2012: Fei Jing; Li-Juan Min; Masaki Mogi; Kousei Ohshima; Akiko Sakata; Ulrike Muscha Steckelings; Kana Tsukuda; Thomas Unger; Björn Dahlöf; Jun Iwanami; Masatsugu Horiuchi
Direct stimulation of angiotensin II type 2 receptor enhances spatial memory.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2012;32(2):248-55.
2012: Masaki Mogi; Jun Iwanami; Masatsugu Horiuchi
Roles of Brain Angiotensin II in Cognitive Function and Dementia.
International journal of hypertension 2012;2012():169649.
2012: Kousei Ohshima; Ulrike Muscha Steckelings; Kana Tsukuda; Tomas Unger; Jun Iwanami; Fei Jing; Li-Juan Min; Masaki Mogi; Akiyoshi Ogimoto; Björn Dahlöf; Jitsuo Higaki; Masatsugu Horiuchi
Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation.
PloS one 2012;7(11):e48387.
2012: Kousei Ohshima; Masaki Mogi; Masatsugu Horiuchi
Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation.
International journal of vascular medicine 2012;2012():508416.
2011: Masaki Mogi; Masatsugu Horiuchi
Is CKD a surrogate marker for predicting cognitive impairment?
Hypertension research : official journal of the Japanese Society of Hypertension 2011;34(12):1251-2.
2011: Jun Iwanami; Masaki Mogi; Masatsugu Horiuchi
[Sympathetic nervous system and renin-angiotensin-aldosterone system in hypertension].
Nihon rinsho. Japanese journal of clinical medicine 2011;69(11):1916-9.
2011: Shinji Inaba; Masaru Iwai; Harumi Kanno; Masaki Mogi; Hideki Okayama; Izumi Senba; Megumi Furuno; Jitsuo Higaki; Masatsugu Horiuchi
Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition.
Journal of hypertension 2011;29(11):2236-45.
2011: Jun Iwanami; Fei Jing; Li-Juan Min; Masaki Mogi; Kousei Ohshima; Akiko Sakata; Kana Tsukuda; Masatsugu Horiuchi
Effect of angiotensin II type 2 receptor deletion in hematopoietic cells on brain ischemia-reperfusion injury.
Hypertension 2011;58(3):404-9.
2011: Masatsugu Horiuchi; Masaki Mogi
Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.
British journal of pharmacology 2011;163(6):1122-30.
2011: Kana Tsukuda; Masaki Mogi; Jun Iwanami; Li-Juan Min; Fei Jing; Kousei Oshima; Masatsugu Horiuchi
Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade.
Biochemical and biophysical research communications 2011;409(2):275-9.
2011: Li-Juan Min; Masaki Mogi; Jun Iwanami; Akiko Sakata; Fei Jing; Kana Tsukuda; Kousei Ohshima; Masatsugu Horiuchi
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Hypertension research : official journal of the Japanese Society of Hypertension 2011;34(6):773-8.
2011: Shinji Inaba; Masaru Iwai; Megumi Furuno; Harumi Kanno; Izumi Senba; Hideki Okayama; Masaki Mogi; Jitsuo Higaki; Masatsugu Horiuchi
Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling.
American journal of hypertension 2011;24(5):550-6.
2011: Masatsugu Horiuchi; Masaki Mogi
C-reactive protein beyond biomarker of inflammation in metabolic syndrome.
Hypertension 2011;57(4):672-3.
2011: Masaki Mogi; Masatsugu Horiuchi
[New antihypertensive drugs including angiotensin II type 2 receptor agonist].
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 2011;100(2):432-40.
2011: Masaki Mogi; Masatsugu Horiuchi
Neurovascular coupling in cognitive impairment associated with diabetes mellitus.
Circulation journal : official journal of the Japanese Circulation Society 2011;75(5):1042-8.
2011: Masaki Mogi; Masatsugu Horiuchi
Clinical Interaction between Brain and Kidney in Small Vessel Disease.
Cardiology research and practice 2011;2011():306189.
2011: Akiko Sakata; Masaki Mogi; Jun Iwanami; Kana Tsukuda; Li-Juan Min; Fei Jing; Kousei Ohshima; Masaharu Ito; Masatsugu Horiuchi
Female type 2 diabetes mellitus mice exhibit severe ischemic brain damage.
Journal of the American Society of Hypertension : JASH 2011;5(1):7-11.
2010: Jun Iwanami; Masaki Mogi; Kana Tsukuda; Li-Juan Min; Akiko Sakata; Fei Jing; Masaru Iwai; Masatsugu Horiuchi
Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Journal of hypertension 2010;28(8):1730-7.
2010: Masaru Iwai; Harumi Kanno; Yumiko Tomono; Shinji Inaba; Izumi Senba; Megumi Furuno; Masaki Mogi; Masatsugu Horiuchi
Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
Journal of hypertension 2010;28(7):1471-81.
2010: Akiko Sakata; Masaki Mogi; Masaharu Ito; Masatsugu Horiuchi
Listening to the sound of silence between men and women.
Hypertension research : official journal of the Japanese Society of Hypertension 2010;33(7):668-9.
2010: Akiko Sakata; Masaki Mogi; Jun Iwanami; Kana Tsukuda; Li-Juan Min; Fei Jing; Masaru Iwai; Masaharu Ito; Masatsugu Horiuchi
Female exhibited severe cognitive impairment in type 2 diabetes mellitus mice.
Life sciences 2010;86(17-18):638-45.
2010: Masatsugu Horiuchi; Masaki Mogi; Masaru Iwai
The angiotensin II type 2 receptor in the brain.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2010;11(1):1-6.
2010: Masaki Mogi; Masatsugu Horiuchi
Remote control of brain angiotensin II levels by angiotensin receptor blockers.
Hypertension research : official journal of the Japanese Society of Hypertension 2010;33(2):116-7.
2009: Li-Juan Min; Masaki Mogi; Kouichi Tamura; Jun Iwanami; Akiko Sakata; Teppei Fujita; Kana Tsukuda; Fei Jing; Masaru Iwai; Masatsugu Horiuchi
Angiotensin II type 1 receptor-associated protein prevents vascular smooth muscle cell senescence via inactivation of calcineurin/nuclear factor of activated T cells pathway.
Journal of molecular and cellular cardiology 2009;47(6):798-809.
2009: Akiko Sakata; Masaki Mogi; Jun Iwanami; Kana Tsukuda; Li-Juan Min; Teppei Fujita; Masaru Iwai; Masaharu Ito; Masatsugu Horiuchi
Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function.
Brain research 2009;1300():14-23.
2009: Masaki Mogi
Learning a lesson from the past.
Hypertension research : official journal of the Japanese Society of Hypertension 2009;32(11):936-7.
2009: Kana Tsukuda; Masaki Mogi; Jun Iwanami; Li-Juan Min; Akiko Sakata; Fei Jing; Masaru Iwai; Masatsugu Horiuchi
Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
Hypertension 2009;54(4):782-7.
2009: Masaki Mogi; Masatsugu Horiuchi
Effects of angiotensin II receptor blockers on dementia.
Hypertension research : official journal of the Japanese Society of Hypertension 2009;32(9):738-40.
2009: Harumi Kanno; Masaru Iwai; Shinji Inaba; Izumi Senba; Hirotomo Nakaoka; Hisako Sone; Masaki Mogi; Masatsugu Horiuchi
Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
Hypertension research : official journal of the Japanese Society of Hypertension 2009;32(8):706-11.
2009: Masaru Iwai; Yumiko Tomono; Shinji Inaba; Harumi Kanno; Izumi Senba; Masaki Mogi; Masatsugu Horiuchi
AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice.
American journal of hypertension 2009;22(7):784-91.
2009: Masaki Mogi; Masatsugu Horiuchi
[New insights of ARB in central nervous system].
Nihon rinsho. Japanese journal of clinical medicine 2009;67(4):735-41.
2009: Jun Iwanami; Masaki Mogi; Masaru Iwai; Masatsugu Horiuchi
Inhibition of the renin-angiotensin system and target organ protection.
Hypertension research : official journal of the Japanese Society of Hypertension 2009;32(4):229-37.
2009: Teppei Fujita; Masaki Mogi; Li-Juan Min; Jun Iwanami; Kana Tsukuda; Akiko Sakata; Hideki Okayama; Masaru Iwai; Clara Nahmias; Jitsuo Higaki; Masatsugu Horiuchi
Attenuation of cuff-induced neointimal formation by overexpression of angiotensin II type 2 receptor-interacting protein 1.
Hypertension 2009;53(4):688-93.
2009: Li-Juan Min; Masaki Mogi; Masaru Iwai; Masatsugu Horiuchi
Signaling mechanisms of angiotensin II in regulating vascular senescence.
Ageing research reviews 2009;8(2):113-21.
2009: Masaki Mogi; Masaru Iwai; Masatsugu Horiuchi
New insights into the regulation of angiotensin receptors.
Current opinion in nephrology and hypertension 2009;18(2):138-43.
2009: Shinji Inaba; Masaru Iwai; Yumiko Tomono; Izumi Senba; Megumi Furuno; Harumi Kanno; Hideki Okayama; Masaki Mogi; Jitsuo Higaki; Masatsugu Horiuchi
Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
American journal of hypertension 2009;22(2):145-50.
2009: Shinji Inaba; Masaru Iwai; Megumi Furuno; Yumiko Tomono; Harumi Kanno; Izumi Senba; Hideki Okayama; Masaki Mogi; Jitsuo Higaki; Masatsugu Horiuchi
Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice.
Hypertension 2009;53(2):356-62.
2009: Shinji Inaba; Masaru Iwai; Yumiko Tomono; Izumi Senba; Megumi Furuno; Harumi Kanno; Hideki Okayama; Masaki Mogi; Jitsuo Higaki; Masatsugu Horiuchi
Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes.
Stroke; a journal of cerebral circulation 2009;40(2):597-603.
2008: Masaki Mogi; Jian-Mei Li; Kana Tsukuda; Jun Iwanami; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Telmisartan prevented cognitive decline partly due to PPAR-gamma activation.
Biochemical and biophysical research communications 2008;375(3):446-9.
2008: Jun Iwanami; Masaki Mogi; Jian-Mei Li; Kana Tsukuda; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice.
Stroke; a journal of cerebral circulation 2008;39(9):2554-9.
2008: Jian-Mei Li; Masaki Mogi; Jun Iwanami; Li-Juan Min; Kana Tsukuda; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density.
Stroke; a journal of cerebral circulation 2008;39(7):2029-36.
2008: Li-Juan Min; Masaki Mogi; Jun Iwanami; Jian-Mei Li; Akiko Sakata; Teppei Fujita; Kana Tsukuda; Masaru Iwai; Masatsugu Horiuchi
Angiotensin II type 2 receptor deletion enhances vascular senescence by methyl methanesulfonate sensitive 2 inhibition.
Hypertension 2008;51(5):1339-44.
2008: Kana Tsukuda; Masaki Mogi; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Diabetes-associated cognitive impairment is improved by a calcium channel blocker, nifedipine.
Hypertension 2008;51(2):528-33.
2008: Yumiko Tomono; Masaru Iwai; Shinji Inaba; Masaki Mogi; Masatsugu Horiuchi
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
American journal of hypertension 2008;21(2):206-12.
2008: Masaru Iwai; Shinji Inaba; Yumiko Tomono; Harumi Kanno; Jun Iwanami; Masaki Mogi; Masatsugu Horiuchi
Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice.
Hypertension research : official journal of the Japanese Society of Hypertension 2008;31(1):161-8.
2008: Masaki Mogi; Kenneth Walsh; Masaru Iwai; Masatsugu Horiuchi
Akt-FOXO3a signaling affects human endothelial progenitor cell differentiation.
Hypertension research : official journal of the Japanese Society of Hypertension 2008;31(1):153-9.
2007: Masaki Mogi; Kana Tsukuda; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan.
Neuropharmacology 2007;53(8):899-905.
2007: Kana Tsukuda; Masaki Mogi; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi
Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
Hypertension 2007;50(6):1099-105.
2007: Masaki Mogi; Masaru Iwai; Masatsugu Horiuchi
Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(12):2532-9.
2007: Li-Juan Min; Masaki Mogi; Jun Iwanami; Jian-Mei Li; Akiko Sakata; Teppei Fujita; Kana Tsukuda; Masaru Iwai; Masatsugu Horiuchi
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
Cardiovascular research 2007;76(3):506-16.
2007: Xinyu Gao; Masaru Iwai; Shinji Inaba; Yumiko Tomono; Harumi Kanno; Masaki Mogi; Masatsugu Horiuchi
Attenuation of monocyte chemoattractant protein-1 expression via inhibition of nuclear factor-kappaB activity in inflammatory vascular injury.
American journal of hypertension 2007;20(11):1170-5.
2007: Jun Iwanami; Masaki Mogi; Shoko Okamoto; Xin-Yu Gao; Jian-Mei Li; Li-Juan Min; Ayumi Ide; Kana Tsukuda; Masaru Iwai; Masatsugu Horiuchi
Pretreatment with eplerenone reduces stroke volume in mouse middle cerebral artery occlusion model.
European journal of pharmacology 2007;566(1-3):153-9.
2007: Teppei Fujita; Masaki Mogi; Masatsugu Horiuchi
[AT1 receptor and AT2 receptor].
Nihon rinsho. Japanese journal of clinical medicine 2007;65 Suppl 4():149-53.
2007: Jian-Mei Li; Masaki Mogi; Kana Tsukuda; Hirokazu Tomochika; Jun Iwanami; Li-Juan Min; Clara Nahmias; Masaru Iwai; Masatsugu Horiuchi
Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1.
Molecular endocrinology (Baltimore, Md.) 2007;21(2):499-511.
2006: Masarsu Iwai; Huan-Sheng Li; Rui Chen; Tetsuya Shiuchi; Lan Wu; Li-Juan Min; Jian-Mei Li; Masahiro Tsuda; Jun Suzuki; Yumiko Tomono; Hirokazu Tomochika; Masaki Mogi; Masatsugu Horiuchi
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
The Journal of pharmacology and experimental therapeutics 2006;319(3):1081-7.
2006: Masaki Mogi; Masaru Iwai; Rui Chen; Jun Iwanami; Ayumi Ide; Kana Tsukuda; Toyofumi Yoshii; Masatsugu Horiuchi
Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice.
American journal of hypertension 2006;19(11):1144-9.
2006: Masaki Mogi; Masatsugu Horiuchi
[Angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers].
Nihon rinsho. Japanese journal of clinical medicine 2006;64 Suppl 7():724-9.
2006: Masaru Iwai; Rui Chen; Ayumi Ide; Jun Iwanami; Hirokazu Tomochika; Yumiko Tomono; Masaki Mogi; Masatsugu Horiuchi
The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Journal of hypertension 2006;24(10):2023-31.
2006: Akira Oshita; Masaru Iwai; Rui Chen; Ayumi Ide; Midori Okumura; Shiori Fukunaga; Toyofumi Yoshii; Masaki Mogi; Jitsuo Higaki; Masatsugu Horiuchi
Attenuation of inflammatory vascular remodeling by angiotensin II type 1 receptor-associated protein.
Hypertension 2006;48(4):671-6.
2006: Meiko Hamai; Masaru Iwai; Ayumi Ide; Hirokazu Tomochika; Yumiko Tomono; Masaki Mogi; Masatsugu Horiuchi
Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
Neuropharmacology 2006;51(4):822-8.
2006: Masaki Mogi; Li-Juan Min; Jian-Mei Li; Masaru Iwai; Masatsugu Horiuchi
[Future directions for antihypertensive drugs].
Nihon rinsho. Japanese journal of clinical medicine 2006;64 Suppl 5():571-5.
2006: Masaki Mogi; Masaru Iwai; Masatsugu Horiuchi
[Cerebroprotection with calcium channel blockers].
Nihon rinsho. Japanese journal of clinical medicine 2006;64 Suppl 5():531-5.
2006: Masaki Mogi; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Kana Tsukuda; Masaru Iwai; Masatsugu Horiuchi
Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2.
Hypertension 2006;48(1):141-8.
2006: Toyofumi Yoshii; Masaru Iwai; Zhen Li; Rui Chen; Ayumi Ide; Shiori Fukunaga; Akira Oshita; Masaki Mogi; Jitsuo Higaki; Masatsugu Horiuchi
Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.
Hypertension research : official journal of the Japanese Society of Hypertension 2006;29(6):457-66.
2006: Jun Suzuki; Masaru Iwai; Masaki Mogi; Akira Oshita; Toyofumi Yoshii; Jitsuo Higaki; Masatsugu Horiuchi
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(4):917-21.
2006: Masatsugu Horiuchi; Masaki Mogi; Masaru Iwai
Signaling crosstalk angiotensin II receptor subtypes and insulin.
Endocrine journal 2006;53(1):1-5.
2006: Lan Wu; Masaru Iwai; Zhen Li; Jian-Mei Li; Masaki Mogi; Masatsugu Horiuchi
Nifedipine inhibited angiotensin II-induced monocyte chemoattractant protein 1 expression: involvement of inhibitor of nuclear factor kappa B kinase and nuclear factor kappa B-inducing kinase.
Journal of hypertension 2006;24(1):123-30.
2005: Masaru Iwai; Rui Chen; Zhen Li; Tetsuya Shiuchi; Jun Suzuki; Ayumi Ide; Masahiro Tsuda; Midori Okumura; Li-Juan Min; Masaki Mogi; Masatsugu Horiuchi
Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Circulation 2005;112(11):1636-43.
2005: Li-Juan Min; Masaki Mogi; Jian-Mei Li; Jun Iwanami; Masaru Iwai; Masatsugu Horiuchi
Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells.
Circulation research 2005;97(5):434-42.
2005: Midori Okumura; Masaru Iwai; Ayumi Ide; Masaki Mogi; Masaharu Ito; Masatsugu Horiuchi
Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression.
Hypertension 2005;46(3):577-83.
2005: Jun Suzuki; Masaru Iwai; Zhen Li; Jian-Mei Li; Li-Juan Min; Ayumi Ide; Toyofumi Yoshii; Akira Oshita; Masaki Mogi; Masatsugu Horiuchi
Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Journal of hypertension 2005;23(7):1383-9.
2005: Jian-Mei Li; Masaru Iwai; Tai-Xing Cui; Li-Juan Min; Masahiro Tsuda; Jun Iwanami; Jun Suzuki; Masaki Mogi; Masatsugu Horiuchi
Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Molecular pharmacology 2005;67(5):1666-73.
2005: Masahiro Tsuda; Masaru Iwai; Jian-Mei Li; Huan-Sheng Li; Li-Juan Min; Ayumi Ide; Midori Okumura; Jun Suzuki; Masaki Mogi; Hiromichi Suzuki; Masatsugu Horiuchi
Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress.
Hypertension 2005;45(4):545-51.
2005: Michiko Abe; Zhihong Wu; Miyuki Yamamoto; Jing-Ji Jin; Yasuharu Tabara; Masaki Mogi; Katsuhiko Kohara; Tetsuro Miki; Jun Nakura
Association of dopamine beta-hydroxylase polymorphism with hypertension through interaction with fasting plasma glucose in Japanese.
Hypertension research : official journal of the Japanese Society of Hypertension 2005;28(3):215-21.
2004: Miyuki Yamamoto; Michiko Abe; Jing-Ji Jin; Zhihong Wu; Yasuharu Tabara; Masaki Mogi; Katsuhiko Kohara; Tetsuro Miki; Jun Nakura
Association of a GNAS1 gene variant with hypertension and diabetes mellitus.
Hypertension research : official journal of the Japanese Society of Hypertension 2004;27(12):919-24.
2004: Miyuki Yamamoto; Michiko Abe; Jing-Ji Jin; Zhihong Wu; Yasuharu Tabara; Masaki Mogi; Katsuhiko Kohara; Tetsuro Miki; Jun Nakura
Association of GNB3 gene with pulse pressure and clustering of risk factors for cardiovascular disease in Japanese.
Biochemical and biophysical research communications 2004;316(3):744-8.